Sees Q4 adjusted EBITDA $6.5M-$7M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD reports Q3 EPS (14c), consensus (12c)
- LifeMD launches affiliated pharmacy to drive end-to-end patient care
- LifeMD launches TestoRx, direct to consumer testosterone replacement therapy
- BTIG says market demand for lower cost GLP1-s should benefit LifeMD, Him & Hers
- LifeMD announces major enhancements to its weight management program